Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Kevin M Kalinsky"'
Autor:
Anne L. Loeser, Lucy Gao, Aditya Bardia, Mark E. Burkard, Kevin M. Kalinsky, Jeffrey Peppercorn, Hope S. Rugo, Martha Carlson, Janice Cowden, Lesley Glenn, Julia Maues, Sheila McGlown, Andy Ni, Natalia Padron, Maryam Lustberg
Publikováno v:
Breast Cancer Research and Treatment. 196:549-563
Although metastatic breast cancer (MBC) is treatable, it is not curable and most patients remain on treatment indefinitely. While oncologists commonly prescribe the recommended starting dose (RSD) from the FDA-approved label, patient tolerance may di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ca9faaa1f93bc033e82dee3f847cef5
https://doi.org/10.1007/s10549-022-06755-5
https://doi.org/10.1007/s10549-022-06755-5
Autor:
Kevin M Kalinsky, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain, Daniel F Hayes, Nancy U Lin, Edith A Perez, Lori A Goldstein, Stephen KL Chia, Sukhbinder Dhesy-Thind, Priya Rastogi, Emilio Alba, Suzette Delaloge, Miguel Martin, Catherine M Kelly, Manuel Ruiz-Borrego, Miguel Gil-Gil, Claudia H Arce-Salinas, Etienne GC Brain, Eun Sook Lee, Jean-Yves Pierga, Begoña Bermejo, Manuel Ramos-Vasquez, Kyung Hae Jung, Jean-Marc Ferrero, Anne Schott, Steven Shak, Priyanka Sharma, Danika Lew, Jieling Miao, Debasish Tripathy, Lajos Pusztai, Gabriel Hortobagyi
Publikováno v:
Cancer Research. 82:GS2-07
Background: We previouslyreported that invasive disease-free survival (IDFS), the primary outcome, and distantdisease-free survival (DDFS), a secondary outcome, differed by menopausalstatus in a pre-specified analysis. Here,we report updates on IDFS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a95210de8eeb612c414b52ca70dc2d77
https://doi.org/10.1158/1538-7445.sabcs21-gs2-07
https://doi.org/10.1158/1538-7445.sabcs21-gs2-07
Autor:
Kevin M Kalinsky, Megan Kruse, Emily Nash Smyth, Claudia M Guimaraes, Santosh Gautam, Alnecia R Nisbett, Maxine D Fisher, Zhanglin Lin Cui, Lee Bowman
Publikováno v:
Cancer Research. 82:P1-18
Background: Cyclin-dependent kinase 4 and 6 inhibitors (CDK4 & 6i) provide significant benefit for patients (pts) with HR+, HER2- MBC, however, clinical questions remain regarding the optimal sequence (seq) of treatments (tx). Prior analyses of real
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::490026f31da88cfb2035767484e51741
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-37
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-37
Autor:
Matthew Ryan Kearney, Rami Vanguri, Qi Wang, Kathleen Fenn, Hua Guo, Douglas Marks, Hanina Hibshoosh, Kevin M Kalinsky, Eileen Connolly
Publikováno v:
Cancer Research. 82:P2-07
Background: Patients (pts) with early stage HER2+ breast cancer (HER2+ EBC) are often treated with neoadjuvant chemotherapy (NACT). Recent studies have demonstrated that increased densities of tumor infiltrating lymphocytes (TIL) are associated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::785bade02189c23c35f0173bad73d4de
https://doi.org/10.1158/1538-7445.sabcs21-p2-07-09
https://doi.org/10.1158/1538-7445.sabcs21-p2-07-09
Autor:
Sibylle Loibl, Sara M. Tolaney, Kevin Punie, Mafalda Oliveira, Hope S. Rugo, Aditya Bardia, Sara A. Hurvitz, Adam Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O’Shaughnessy, Lisa A. Carey, Luca Gianni, Véronique Diéras, Ling Shi, Mahdi Gharaibeh, Luciana Preger, Lee Moore, See Phan, Martine Piccart
Publikováno v:
Cancer Research. 82:P5-16
Background: In ASCENT, patients with mTNBC refractory to or relapsing after ≥2 prior chemotherapies (at least one in the metastatic setting) were randomized 1:1 to receive sacituzumab govitecan (SG) or single-agent treatment of physician’s choice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42bd412c4d3acaa8d1d28340bec49ee4
https://doi.org/10.1158/1538-7445.sabcs21-p5-16-01
https://doi.org/10.1158/1538-7445.sabcs21-p5-16-01
Autor:
Anne L Loeser, Aditya Bardia, Mark E. Burkard, Kevin M Kalinsky, Jeffrey Peppercorn, Hope S. Rugo, Martha Carlson, Janice Cowden, Julia Maues, Sheila McGlown, Maryam Lustberg
Publikováno v:
Cancer Research. 82:P4-10
Background: MBC is generally incurable and most patients will remain on treatment indefinitely. Medical oncologists commonly prescribe the Recommended Starting Dose (RSD) from the FDA-approved label based upon clinical trial results, with lower doses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3bd068cf5ea628f344d46c6e242dee2
https://doi.org/10.1158/1538-7445.sabcs21-p4-10-09
https://doi.org/10.1158/1538-7445.sabcs21-p4-10-09
Autor:
Ian Krop, Erika Hamilton, Kyung Hae Jung, Shanu Modi, Kevin M Kalinsky, Gail Phillips, Rong Shi, Sharareh Monemi, Michael Mamounas, Ola Saad, Voleak Choeurng, Renee Commerford, Eunpi Cho, Alexander Ungewickell, Patricia LoRusso
Publikováno v:
Cancer Research. 82:P2-13
Background: Despite the success of multiple HER2-targeted agents in HER2+ breast cancer (BC), resistance remains a challenge and novel therapies are needed. DHES0815A is a THIOMABTM antibody-drug conjugate consisting of a humanized IgG1 anti-HER2 mon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a432ee417e4dfc6c109e27c84cba065a
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-25
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-25
Autor:
Javier Cortés, Aditya Bardia, Delphine Loirat, Sara M. Tolaney, Kevin Punie, Mafalda Oliveira, Sara A. Hurvitz, Adam Brufsky, Sagar Sardesai, Kevin M Kalinsky, Tiffany Traina, Erika Hamilton, Joyce O’Shaughnessy, Véronique Diéras, Lisa A. Carey, Martine Piccart, Sibylle Loibl, Hope S. Rugo, Yanni Zhu, See Phan, Luca Gianni
Publikováno v:
Cancer Research. 82:P5-16
Background: SG is an antibody-drug conjugate composed of an anti-Trop-2 antibody coupled to the cytotoxic SN-38 payload via a proprietary, hydrolyzable linker. SG is FDA approved for pts with mTNBC who received ≥2 prior chemotherapies (≥1 in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::236132dbab270597461130e10b6fe66f
https://doi.org/10.1158/1538-7445.sabcs21-p5-16-15
https://doi.org/10.1158/1538-7445.sabcs21-p5-16-15
Autor:
A. Jo Chien, Kevin M Kalinsky, Julissa Molina-Vega, Rita Mukhtar, Karthik Giridhar, Olufunmilayo I Olopade, Amrita Basu, Smita M Asare, Paul Henderson, Gillian Hirst, Ruixiao Lu, Ella Jones, Nola Hylton, Lamorna Brown-Swigart, Laura J van 't Veer, Douglas Yee, Ingrid Mayer, Laura J Esserman
Publikováno v:
Cancer Research. 82:OT1-10
Background: There is no clinical equipoise on the best upfront management of patients with early-stage hormone receptor-positive (HR+)/HER2-negative (HER2-) breast cancer (BC) that is high-risk by clinicopathologic criteria, and low-risk based on mol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58a72e7aff74ff9a45915a92aa8f48e2
https://doi.org/10.1158/1538-7445.sabcs21-ot1-10-02
https://doi.org/10.1158/1538-7445.sabcs21-ot1-10-02
Autor:
Prabhjot S. Mundi, Filemon S. Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R. Rainey, Kristina C. Guillan, Armaan Siddiquee, Daoqi You, Ronald Realubit, Charles Karan, Michael V. Ortiz, Eugene F. Douglass, Melissa Accordino, Suzanne Mistretta, Frances Brogan, Jeffrey N. Bruce, Cristina I. Caescu, Richard Carvajal, Katherine Crew, Guarionex Decastro, Mark Heaney, Brian Henick, Dawn Hershman, June Hou, Fabio Iwamoto, Joseph Jurcic, Ravi P. Kiran, Michael Kluger, Teri Kreisl, Nicole Lamanna, Andrew Lassman, Emerson Lim, Gulam A. Manji, Guy McKhann, James McKiernan, Alfred I. Neugut, Kenneth Olive, Todd Rosenblat, Gary K. Schwartz, Catherine Shu, Michael Sisti, Ana Tergas, Reena Vattakalam, Mary Welch, Sven Wenske, Jason D. Wright, Hanina Hibshoosh, Kevin M. Kalinsky, Mahalaxmi Aburi, Peter A. Sims, Mariano J. Alvarez, Andrew L. Kung, Andrea Califano
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b58393c179b0e2f8283d6ee880918df
https://doi.org/10.2139/ssrn.4069033
https://doi.org/10.2139/ssrn.4069033